Practical psychopharmacology. (Cognitive Impairment in Schizophrenia).(Brief Article): An article from: Clinical Psychiatry News

This digital document is an article from Clinical Psychiatry News, published by International Medical News Group on February 1, 2002. The length of the article is 929 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Practical psychopharmacology. (Cognitive Impairment in Schizophrenia).(Brief Article)
Author: Carl Sherman
Publication: Clinical Psychiatry News (Magazine/Journal)
Date: February 1, 2002
Publisher: International Medical News Group
Volume: 30 Issue: 2 Page: 12(2)

Article Type: Brief Article

Distributed by Thomson Gale

CHECK PRICE NOW!
Read Full Review >>

Glutaminergics promising for cognitive, negative symptoms: amino acids for schizophrenia.(Adult Psychiatry): An article from: Clinical Psychiatry News

This digital document is an article from Clinical Psychiatry News, published by International Medical News Group on October 1, 2003. The length of the article is 502 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Glutaminergics promising for cognitive, negative symptoms: amino acids for schizophrenia.(Adult Psychiatry)
Author: Carl Sherman
Publication: Clinical Psychiatry News (Magazine/Journal)
Date: October 1, 2003
Publisher: International Medical News Group
Volume: 31 Issue: 10 Page: 24(1)

Distributed by Thomson Gale

CHECK PRICE NOW!
Read Full Review >>

Practical psychopharmacology: Psychosocial approaches complement medication in schizophrenia treatment. (Psychopharmacology).: An article from: Clinical Psychiatry News

This digital document is an article from Clinical Psychiatry News, published by International Medical News Group on April 1, 2002. The length of the article is 1058 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Practical psychopharmacology: Psychosocial approaches complement medication in schizophrenia treatment. (Psychopharmacology).
Author: Carl Sherman
Publication: Clinical Psychiatry News (Magazine/Journal)
Date: April 1, 2002
Publisher: International Medical News Group
Volume: 30 Issue: 4 Page: 23(1)

Distributed by Thomson Gale

CHECK PRICE NOW!
Read Full Review >>

Let symptoms guide schizophrenia treatment.(Adult Psychiatry): An article from: Clinical Psychiatry News

This digital document is an article from Clinical Psychiatry News, published by International Medical News Group on May 1, 2004. The length of the article is 628 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Let symptoms guide schizophrenia treatment.(Adult Psychiatry)
Author: Carl Sherman
Publication: Clinical Psychiatry News (Magazine/Journal)
Date: May 1, 2004
Publisher: International Medical News Group
Volume: 32 Issue: 5 Page: 33(1)

Distributed by Thomson Gale

CHECK PRICE NOW!
Read Full Review >>

Staying Well After Psychosis: A Cognitive Interpersonal Approach to Recovery and Relapse Prevention

Staying Well After Psychosis: A Cognitive Interpersonal Approach to Recovery and Relapse Prevention
Staying Well After Psychosis is extremely readable, based on solid research evidence and packed full of clinical insights and strategies that will satisfy any clinician seeking innovative approaches to the promotion of recovery from psychosis.”
—Anthony P. Morrison, Professor of Clinical Psychology, University of Manchester, UK

Over the past decade our understanding of the experience of psychosis has changed dramatically. As part of this change, a range of psychological models of psychosis and associated interventions have developed.

Staying Well After Psychosis presents an individually based psychological intervention targeting emotional recovery and relapse prevention. This approach considers the cognitive, interpersonal and developmental aspects involved in recovery and vulnerability to the recurrence of psychosis.

Andrew Gumley and Matthias Schwannauer provide a framework for recovery and staying well that focuses on emotional and interpersonal adaptation to psychosis. This practical manual covers, in detail, all aspects of the therapeutic process of Cognitive Interpersonal Therapy, including:

  • Taking a developmental perspective on help seeking and affect regulation.
  • Supporting self-reorganisation and adaptation after acute psychosis.
  • Understanding and treating traumatic reactions to psychosis.
  • Working with humiliation, entrapment, loss and fear of recurrence appraisals during recovery.
  • Working with cognitive interpersonal schemata.
  • Developing coping in an interpersonal context.

Clinical psychologists, psychiatrists and mental health professionals will find this innovative treatment manual to be a valuable resource in their work with adults and adolescents. This book will also be of interest to lecturers and students of clinical psychology and mental health.

CHECK PRICE NOW!
Read Full Review >>

Schizophrenia prodrome therapies show promise: early intervention with antipsychotics and CBT appears to delay or prevent psychotic breaks.(Adult Psychiatry): An article from: Clinical Psychiatry News

This digital document is an article from Clinical Psychiatry News, published by Thomson Gale on October 1, 2005. The length of the article is 1373 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Schizophrenia prodrome therapies show promise: early intervention with antipsychotics and CBT appears to delay or prevent psychotic breaks.(Adult Psychiatry)
Author: Diana Mahoney
Publication: Clinical Psychiatry News (Magazine/Journal)
Date: October 1, 2005
Publisher: Thomson Gale
Volume: 33 Issue: 10 Page: 22(1)

Distributed by Thomson Gale

CHECK PRICE NOW!
Read Full Review >>

Narrative CBT for Psychosis

Narrative CBT for Psychosis

Designed to meet the complex needs of patients with psychosis, Narrative CBT for Psychosis combines narrative and solution-focused therapy with established techniques from CBT (cognitive behaviour therapy) into one integrated flexible approach.

In this book John Rhodes and Simon Jakes bring the practitioner up-to-date, as treatment and practice evolve to draw on other therapeutic approaches, creating an approach which is client centred and non-confrontational. The book contains many tried and tested practical ideas for helping clients, with several chapters including detailed and illuminating case studies.

Areas of discussion include:

  • how to work with delusions, voices and visions
  • working with core beliefs
  • an exploration of narratives of past difficulties and traumas
  • recovery and ending therapy

Narrative CBT for Psychosis will be essential reading for all mental health professionals who deal with psychosis who wish to learn a new approach.

CHECK PRICE NOW!
Read Full Review >>

Negative Symptom and Cognitive Deficit Treatment Response in Schizophrenia

Negative Symptom and Cognitive Deficit Treatment Response in Schizophrenia
For the first time in a single volume, distinguished experts address the complex issuesAissues rarely confronted in empirical studies of patients with schizophreniaAand controversial research surrounding the assessment of negative symptoms and cognitive deficits in patients with schizophrenia. Despite recent advances in our understanding of schizophrenia, still notably absent is consensus in assessing negative symptom treatment response. What is the most effective assessment methodAgiven the varying methodologies and contradictory results to date? What constitutes an adequate response? Which medicationAnone is specifically indicated and licensed for negative symptom treatmentAyields the best results? What are the indications for use of this medication? Which instrument best measures negative symptom treatment response (eight rating scales are analyzed here)? Reaching consensus among clinicians and researchers alike is even more difficult because assessment is often thwarted by extrapyramidal side effects of medications, similarities to depressive symptoms, and secondary effects of psychotic experiences. In addition to clarifying these pressing issues, Negative Symptom and Cognitive Deficit Treatment Response in Schizophrenia also discusses -The importance of measuring the experience of emotion versus the more traditional objectively measured symptoms in patients with schizophrenia, and how deficits in emotional experience may resist treatmentAeven in treatment-responsive patients. -The family as an often overlooked source of information about negative symptom improvement or worsening, and the impact of negative symptoms on patientsA relatives. -How treatment affects social functioning and subjective experience of Aquality of life,A and the importance of neurocognitive dysfunction in the social deficits of schizophrenia, which often persist despite significant amelioration of other symptoms. -Specific guidelines for assessing neurocognitive treatment response. Cognitive enhancement is a major factor in improving the quality of patientsA lives. -The latest research on the neurobiology of negative symptoms, including the role of various neurotransmitter systems and brain regions in mediating negative symptom pathology. Also discussed is single vs. multiple pathophysiological processes and single treatment modality vs. distinct treatments for different aspects of negative symptoms. -How to distinguish ApureA negative symptoms from deficit symptoms (i.e., those that persist for at least 1 year and are not secondary to factors such as depression, medication side effects, anxiety, delusions, and hallucinations), and which treatment is indicated for each. Highlighted by patient vignettes, this in-depth guide will be welcomed by all clinicians who treat patients with schizophrenia and want to know and document whether their interventions ameliorate negative symptoms and cognitive dysfunction, and by all researchers who study schizophrenia, particularly those interested in clinical issues and treatment studies.

CHECK PRICE NOW!
Read Full Review >>

Narrative CBT for Psychosis

Narrative CBT for Psychosis

CHECK PRICE NOW!
Read Full Review >>

Is there evidence that cognitive behaviour therapy is an effective treatment for schizophrenia? A cautious or cautionary tale? [An article from: Behaviour Research and Therapy]

Is there evidence that cognitive behaviour therapy is an effective treatment for schizophrenia? A cautious or cautionary tale? [An article from: Behaviour Research and Therapy]
This digital document is a journal article from Behaviour Research and Therapy, published by Elsevier in 2004. The article is delivered in HTML format and is available in your Amazon.com Media Library immediately after purchase. You can view it with any web browser.

Description:
Schizophrenia is a severe and disabling disorder with considerable psychological, social and economic costs. Over the last 15 years there has been a significant development in the use of cognitive behaviour therapy for psychosis (CBTp) in the treatment of schizophrenia, with 20 randomised controlled trials having been published. The majority of this work has been with alleviating medication resistant symptoms in chronic patients, but preliminary work has also been carried out with speeding recovery in acute schizophrenia and in relapse prevention and early intervention. A review of these studies indicates modest effect sizes, with the strongest evidence available for chronic patients. There is evidence that the effect size of the trials is significantly and negatively correlated to their methodological quality. We conclude cautiously that overall there is good evidence for the efficacy and effectiveness of CBTp in the treatment of schizophrenia.
CHECK PRICE NOW!
Read Full Review >>